How can public-private pilot facilities bridge the lab-to-market gap in Indian biotechnology?

India's biotechnology strength shows in publications, patents and a bioeconomy that has expanded rapidly over the last decade, yet commercial translation lags at the costly step between bench proof-of-concept and a full-scale plant. Public-private pilot facilities occupy precisely this "valley of death", and the BioE3 Policy, approved by the Union Cabinet in August 2024, institutionalises them [2].

The nature of the gap

• Scale-up risk: laboratory yields rarely survive tonne-scale operation, and firms lack techno-economic data to commit capital.
• Missing shared infrastructure: start-ups, SMEs and academia have little access to pilot and pre-commercial biomanufacturing capacity; process technology is often imported [2].

How pilot facilities bridge it

• Public capital absorbs the risky middle: a ₹75 crore BIRAC grant supports a 100 TPA pilot-scale R&D facility for polylactic acid (PLA) and co-polymers at Kumbhi, Uttar Pradesh, hosted by Balrampur Chini Mills, enabling the September 2026 commercial launch of bio-based biodegradable plastic [1].
• Bankable evidence: pilots generate process know-how and techno-economic data that lenders and investors need before financing commercial plants [1].
• Customer validation and indigenisation: buyers test specialised grades, while domestic process technology and trained personnel replace imported know-how [1].
• Value-chain anchoring: renewable sugar feedstock is converted into high-value materials, and BioE3's Biomanufacturing hubs, Bio-AI hubs and Biofoundry — including the DBT-BIRAC मूलांकुर call — extend the model to tier-II and tier-III towns [2][3].

Conditions for success

• Regulatory alignment: compostable and biodegradable plastics require prescribed standards such as IS 17088 and CPCB certification before sale, so a DBT-funded pilot must plan the environment-ministry gate early [4].
• Feedstock planning: sugar is contested — ethanol blending reached about 19% by July 2025, and mills are being aided to shift to multi-feedstock plants [5]; pilots should therefore prove non-food biomass routes.

Pilot facilities thus let the state finance uncertainty while industry carries scale, converting research spending into de-risked, investable technology. Expanded with standards, feedstock planning and end-of-life infrastructure, this model can make India a global biomanufacturing base and advance the circular bioeconomy central to green growth.